Iasodopa

Fluorodopa, the active ingredient in Iasodopa, is a radiopharmaceutical presented as an injectable for intravenous use. It enables positron emission tomography (PET) imaging of dopaminergic neuronal activity and is employed in the diagnostic evaluation of Parkinson's disease and related neuroendocrine conditions.

GNH USA supplies Iasodopa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide.

Iasodopa is used to visualize dopaminergic pathways and assist in the diagnosis of movement and neuroendocrine disorders.

- Parkinson's disease: provides quantitative PET imaging of striatal dopamine synthesis to support diagnosis and disease staging. - Neuroendocrine tumors: highlights somatostatin‑receptor positive lesions for accurate tumor localization. - Research studies: serves as a tracer for investigating brain dopamine metabolism in clinical and academic investigations.

Adverse reactions are generally mild and related to the radiopharmaceutical nature of the product.

Common Side Effects: - Nausea: transient feeling of queasiness after injection. - Headache: mild to moderate discomfort lasting a short period. - Injection site pain: brief soreness at the venipuncture site. - Transient flushing: brief skin redness or warmth. - Mild dizziness: temporary light‑headedness. - Fatigue: short‑term tiredness post‑procedure.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals. - Radiation‑induced tissue injury: unlikely but possible with high cumulative exposure. - Severe hypotension: abrupt drop in blood pressure following administration. - Cardiac arrhythmia: rare disturbances in heart rhythm. - Acute renal impairment: potential impact on kidney function in vulnerable patients. - Neurotoxicity: extremely rare, related to excessive dopaminergic stimulation.

Prior to administration, clinicians should evaluate patient‑specific factors and follow radiation safety guidelines.

- Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal radiation risk. - Breastfeeding: discontinue breastfeeding for an appropriate interval after dosing. - Renal function: assess kidney performance, as impaired clearance may increase radiation exposure. - Concomitant PET tracers: schedule appropriately to prevent image interference. - Radiation safety: ensure staff and environment adhere to institutional radiation protection protocols. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fluorodopa may interact with other agents that affect dopaminergic pathways or imaging quality.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may cause overlapping signals and compromise image interpretation. - High‑dose dopamine agonists: can compete for neuronal uptake, reducing tracer accumulation.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may alter dopaminergic signaling and affect tracer distribution. - MAO inhibitors: can modify dopamine metabolism, potentially influencing imaging results. - Contrast agents: may affect PET image quality if administered close in time. - Sedatives: may impact patient movement and image clarity.